Company: FTII
Filing Date: 2025-01-28
Form Type: 10-Q
Source: 0001493152-25-004006
Chunk: 6

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-01-28
Form: 10-Q
Item: Part I, Item 2
Chunk 6
---
 Charter Amendment was filed as Exhibit 3.1 to the Form 8-K filed by the Company on November 22,
2024.

In
connection with the votes to approve the Third Charter Amendment, the holders of 1,564,549 public shares of our Class A common stock
properly exercised their right to redeem their shares for cash at a redemption price of approximately $11.01 per share as disclosed in
the Proxy Statement. The Company is working on calculating the actual redemption price for the Third Extension and intends to disclose it by filing a Current Report on Form 8-K as soon as it is available.

On
November 20, 2024, the Company caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend
the period of time it has to consummate its initial Business Combination from November18, 2024 to December 18, 2024. On December 18,
2024, the Company caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend the period
of time it has to consummate its initial Business Combination from December 18, 2024 to January 18, 2025. On January 18, 2025, the Company
caused to be deposited $37,744 into the Company’s Trust account, allowing the Company to extend the period of time it has to
consummate its initial Business Combination from January 18, 2025 to February 18, 2025.

As
of September 30, 2024, there was $3,300,000 outstanding under the Extension Loans from the Sponsor. As of the date hereof, there is
approximately $3,400,000 outstanding under the Extension Loans from the Sponsor.

5

Recent
Developments

Business
Combination

On
September 16, 2024, the Company, entered into a Merger Agreement”, by and among the Company, Longevity, LBI Merger Sub, Inc., and
Bradford A. Zakes, solely in the capacity as seller representative.

Pursuant
to the Merger Agreement, the parties thereto will enter into the Transactions, pursuant to which, among other things, immediately following
the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc. and Aegeria Soft Tissue LLC, Longevity will merge
with and into LBI Merger Sub, with Longevity as